Cargando…
Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms
Dipeptidyl peptidase 4 (DPP4) inhibitors are a class of antidiabetic medications that cause glucose-dependent increase in incretins in diabetic patients. One of the two incretins, glucagon-like peptide-1 (GLP-1), beside its insulinotropic activity, has been studied for extra pancreatic effects. Most...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568460/ https://www.ncbi.nlm.nih.gov/pubmed/35945358 http://dx.doi.org/10.1007/s00210-022-02279-3 |
_version_ | 1784809640988508160 |
---|---|
author | Zakaria, Esraa M. Tawfeek, Walaa M. Hassanin, Mohamed H. Hassaballah, Mohammed Y. |
author_facet | Zakaria, Esraa M. Tawfeek, Walaa M. Hassanin, Mohamed H. Hassaballah, Mohammed Y. |
author_sort | Zakaria, Esraa M. |
collection | PubMed |
description | Dipeptidyl peptidase 4 (DPP4) inhibitors are a class of antidiabetic medications that cause glucose-dependent increase in incretins in diabetic patients. One of the two incretins, glucagon-like peptide-1 (GLP-1), beside its insulinotropic activity, has been studied for extra pancreatic effects. Most of DPP4 inhibitors (DPP4i) have been investigated in in vivo and in vitro models of diabetic and nondiabetic cardiovascular diseases including heart failure, hypertension, myocardial ischemia or infarction, atherosclerosis, and stroke. Results of preclinical studies proved prominent therapeutic potential of DPP4i in cardiovascular diseases, regardless the presence of diabetes. This review aims to present an updated summary of the cardiovascular protective and therapeutic effects of DPP4 inhibitors through the past 5 years focusing on the molecular mechanisms beneath these effects. Additionally, based on the results summary presented here, future studies may be conducted to elucidate or illustrate some of these findings which can add clinical benefits towards management of diabetic cardiovascular complications. |
format | Online Article Text |
id | pubmed-9568460 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-95684602022-10-16 Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms Zakaria, Esraa M. Tawfeek, Walaa M. Hassanin, Mohamed H. Hassaballah, Mohammed Y. Naunyn Schmiedebergs Arch Pharmacol Review Dipeptidyl peptidase 4 (DPP4) inhibitors are a class of antidiabetic medications that cause glucose-dependent increase in incretins in diabetic patients. One of the two incretins, glucagon-like peptide-1 (GLP-1), beside its insulinotropic activity, has been studied for extra pancreatic effects. Most of DPP4 inhibitors (DPP4i) have been investigated in in vivo and in vitro models of diabetic and nondiabetic cardiovascular diseases including heart failure, hypertension, myocardial ischemia or infarction, atherosclerosis, and stroke. Results of preclinical studies proved prominent therapeutic potential of DPP4i in cardiovascular diseases, regardless the presence of diabetes. This review aims to present an updated summary of the cardiovascular protective and therapeutic effects of DPP4 inhibitors through the past 5 years focusing on the molecular mechanisms beneath these effects. Additionally, based on the results summary presented here, future studies may be conducted to elucidate or illustrate some of these findings which can add clinical benefits towards management of diabetic cardiovascular complications. Springer Berlin Heidelberg 2022-08-10 2022 /pmc/articles/PMC9568460/ /pubmed/35945358 http://dx.doi.org/10.1007/s00210-022-02279-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Zakaria, Esraa M. Tawfeek, Walaa M. Hassanin, Mohamed H. Hassaballah, Mohammed Y. Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms |
title | Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms |
title_full | Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms |
title_fullStr | Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms |
title_full_unstemmed | Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms |
title_short | Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms |
title_sort | cardiovascular protection by dpp-4 inhibitors in preclinical studies: an updated review of molecular mechanisms |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568460/ https://www.ncbi.nlm.nih.gov/pubmed/35945358 http://dx.doi.org/10.1007/s00210-022-02279-3 |
work_keys_str_mv | AT zakariaesraam cardiovascularprotectionbydpp4inhibitorsinpreclinicalstudiesanupdatedreviewofmolecularmechanisms AT tawfeekwalaam cardiovascularprotectionbydpp4inhibitorsinpreclinicalstudiesanupdatedreviewofmolecularmechanisms AT hassaninmohamedh cardiovascularprotectionbydpp4inhibitorsinpreclinicalstudiesanupdatedreviewofmolecularmechanisms AT hassaballahmohammedy cardiovascularprotectionbydpp4inhibitorsinpreclinicalstudiesanupdatedreviewofmolecularmechanisms |